The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Practical considerations for CAR-T therapy in lymphoma
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses practical considerations for the use of chimeric antigen receptor (CAR) T-cell therapies in lymphoma. Prof. Jäger talks on the findings of a study of 500 patients receiving CAR-T therapy in the real-world setting, highlighting the importance of careful patient selection whilst also commenting on benefits seen in patients who may not have appeared optimal candidates. Prof. Jäger also discusses the safety and toxicity of CAR-T therapies, in particular for tisagenlecleucel (tisa-cel). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
